Human IgG1 antibodies suppress angiogenesis in a target-independent manner

Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world’s population. The most widely used anti-angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does not recognize mouse Vegfa, it inhibits angiogenesis in mi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Signal Transduct Target Ther
Asıl Yazarlar: Bogdanovich, Sasha, Kim, Younghee, Mizutani, Takeshi, Yasuma, Reo, Tudisco, Laura, Cicatiello, Valeria, Bastos-Carvalho, Ana, Kerur, Nagaraj, Hirano, Yoshio, Baffi, Judit Z, Tarallo, Valeria, Li, Shengjian, Yasuma, Tetsuhiro, Arpitha, Parthasarathy, Fowler, Benjamin J, Wright, Charles B, Apicella, Ivana, Greco, Adelaide, Brunetti, Arturo, Ruvo, Menotti, Sandomenico, Annamaria, Nozaki, Miho, Ijima, Ryo, Kaneko, Hiroki, Ogura, Yuichiro, Terasaki, Hiroko, Ambati, Balamurali K, Leusen, Jeanette HW, Langdon, Wallace Y, Clark, Michael R, Armour, Kathryn L, Bruhns, Pierre, Verbeek, J Sjef, Gelfand, Bradley D, De Falco, Sandro, Ambati, Jayakrishna
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4763941/
https://ncbi.nlm.nih.gov/pubmed/26918197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sigtrans.2015.1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller